Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term bevacizumab. Found 27 abstracts

no pagination
Koch C, Schwing AM, Herrmann E, Borner M, Diaz-Rubio E, Dotan E, Feliu J, Okita N, Souglakos J, Arkenau HT, Porschen R, Koopman M, Punt CJ, de Gramont A, Tournigand C, Zeuzem S, Trojan J. Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: An individual patient data based meta-analysis. Oncotarget. 2018 Feb 13;9(12):10272-83.   PMCID: PMC5828201
Meropol NJ, Feng Y, Grem JL, Mulcahy MF, Catalano PJ, Kauh JS, Hall MJ, Saltzman JN, George TJ, Zangmeister J, Chiorean EG, Cheema PS, O'Dwyer PJ, Benson AB. Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer. 2018 Feb 15;124(4):688-97.   PMCID: PMC6226304
Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol. 2014 Jan;25(1):132-8.   PMCID: No NIH funds
de Jesus-Gonzalez N, Robinson E, Penchev R, von Mehren M, Heinrich MC, Tap W, Wang Q, Demetri G, George S, Humphreys BD. Regorafenib Induces Rapid and Reversible Changes in Plasma Nitric Oxide and Endothelin-1. American Journal of Hypertension. 2012 Oct;25(10):1118-23.   PMCID: PMC 3578478
Dotan E, Meropol NJ, Zhu F, Zambito F, Bove B, Cai KQ, Godwin AK, Golemis EA, Astsaturov I, Cohen SJ. Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer. British Journal of Cancer. 2012 Feb;106(4):748-55.   PMCID: PMC3322945
Kimbrell HZ, Gustafson KS, Huang M, Ehya H. Subclassification of Non-Small Cell Lung Cancer by Cytologic Sampling: A Logical Approach with Selective Use of Immunocytochemistry. Acta Cytologica. 2012 Jan;56(4):419-24.
Kozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, Carpeno JD, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. British Journal of Cancer. 2012 Oct;107(8):1277-85.   PMCID: PMC3494447
Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. British Journal of Cancer. 2012 Oct;107(8):1268-76.
Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. British Journal of Cancer. 2012 Oct;107(8):1268-76.   PMCID: PMC3494424
Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2012 Oct;127(1):70-4.   PMCID: PMC 3748717
Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN. Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases. Journal of Clinical Oncology. 2012 Dec;30(36):4566-72.   PMCID: PMC3518730
Sill MW, Rubinstein L, Litwin S, Yothers G. A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials. Clinical Trials. 2012 Aug;9(4):385-95.   PMCID: PMC 3598604
Stehman FB, Brady MF, Thigpen JT, Rossi EC, Burger RA. Cytokine use and survival in the first-line treatment of ovarian cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology. 2012 Dec;127(3):495-501.   PMCID: PMC3496007
Tang PA, Cohen SJ, Kollmannsberger C, Bjarnason G, Virik K, MacKenzie MJ, Lourenco L, Wang L, Chen A, Moore MJ. Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer. Clinical Cancer Research. 2012 Nov;18(21):6023-31.
Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu ZH, Watson JC, Weiner LM, Cohen SJ. Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology-Cancer Clinical Trials. 2011 Feb;34(1):70-5.   PMCID: PMC3030655
Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ. A phase II, single-arm study of the anti-alpha 5 beta 1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecologic Oncology. 2011 May;121(2):273-9.   PMCID: not NIH funded
Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Vrionis FD, Wen PY. Central Nervous System Cancers. Journal of the National Comprehensive Cancer Network. 2011 Apr;9(4):352-400.   PMCID: not NIH funded
Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research. 2011 Jun;13(3):R67.   PMCID: PMC3218956
Heath EI, Blumenschein GR, Cohen RB, LoRusso PM, LoConte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemotherapy and Pharmacology. 2011 Sep;68(3):703-12.   PMCID: not NIH funded
Plimack ER, Hudes GR. Selecting Targeted Therapies for Patients With Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network. 2011 Sep;9(9):997-1007.   PMCID: not NIH funded
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term bevacizumab

bevacizumab chemotherapy colorectal-cancer angiogenesis therapy combination trial metastatic breast-cancer cell lung-cancer metaanalysis cancer growth-factor expression phase-iii trial resistance breast-cancer clinical-trials endothelial growth-factor 1990 lkman j-journal of the national cancer institute-v82-p4 carcinoma pharmacokinetics growth irinotecan cisplatin pathology receptors paclitaxel axitinib-docetaxel-capecitabine-solid tumours ag-013736 randomized phase-iii bms-354825 efficacy recurrent interferon-alpha brain metastases cells cell lung-carcinoma cetuximab medulloblastoma progression long-term survival liposomal complications metastatic colorectal cancer pancreatic-cancer raf kinase Male prognostic scoring system hypertension adverse effects antiangiogenic therapy renal cell Female gamma-knife surgery 2008 iorean eg-v26-p2008 randomized-trial plus gemcitabine alpha(5)beta(1) integrin neoadjuvant chemotherapy Kaplan-Meier Estimate cervical-cancer immunohistochemical markers colon cancer Bayer advisor for Roche Hellas JF received advisory fees from Amgen-Roche solid tumors elderly predictive factors brain tumor lung-cancer Lung Neoplasms pancreatic adenocarcinoma experience metabolism plasma-levels persistent Platinum resistant 5-fluorouracil classification NCCN Guidelines anemia Sunitinib oncology-group Teijin Pharma Novartis Pharma-Otsuka Pharmaceuticals and Taiho Pharma JS PTEN (JNCCN 2011 thymidylate synthase adenocarcinoma Antiangiogenesis ttf-1 Servier and Genomica ED received research support to the institution from MSD p63 aurora kinase A Volociximab dexamethasone pathway KRAS mutation Middle Aged Ovarian cancer high-dose blood pressure antiangiogenic therapy-endothelin-1-hypertension-nitric oxide NCCN Clinical Practice Guidelines Chemotherapy a gene Merck-Serono received research funding (for the institution) from Roche-Amgen coagulation glioblastoma 1975 cock sj-biometrics-v31-p103 kidney neoplasms NSCLC prognostic factors phase-ii trial tyrosine kinase centrosome amplification 1st-line treatment system inhibitor Carcinoma interests mortality circulating tumor-cells Non-Small-Cell Lung Carcinoma radiotherapy plus concomitant 2010 dermott df-v28 sunitinib pathological response Sanofi and Roche and acted as medical received research grants from Amgen Proportional Hazards Models kinase inhibitor alpha 5 beta 1 integrin colorectal cancer brain radiation-therapy differential-diagnosis panitumumab oxaliplatin copy number Bayer Oncomed-Pfizer and Biocompatibles JT received advisory fees from Amgen Paclitaxel genetics Imidazoles alpha solid Treatment Outcome biomarker average-risk medulloblastoma evaluate caveolin-1 doxorubicin Indazoles survival medullary Bevacizumab tumors
Last updated on Monday, August 10, 2020